<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128191</url>
  </required_header>
  <id_info>
    <org_study_id>2013-07-129</org_study_id>
    <nct_id>NCT02128191</nct_id>
  </id_info>
  <brief_title>No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants</brief_title>
  <official_title>Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of no treatment compared
      with ibuprofen treatment for patent ductus arteriosus in preterm infants. The study
      hypothesis is that no treatment is not inferior to oral ibuprofen treatment in preterm
      infants. (non-inferiority study)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, non-inferiority clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of moderate to severe bronchopulmonary dysplasia (BPD) or mortality at 36 weeks postmenstrual age (PMA)</measure>
    <time_frame>36 weeks PMA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate to severe BPD</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oxygen dependency at 40 weeks PMA</measure>
    <time_frame>40 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>28-days since birth and 36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of intraventricular hemorrhage (grade 3 or greater)</measure>
    <time_frame>28-days since birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of retinopathy of prematurity (stage III or greater)</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of necrotizing enterocolitis (stage 2b or greater)</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PDA</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intubation</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of nasal continuous positive airway pressure (NCPAP) treatment</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of oxygen use</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth velocity</measure>
    <time_frame>40 weeks PMA (± 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Bronchopulmonary Dysplasia (BPD)</condition>
  <arm_group>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ibuprofen</intervention_name>
    <description>Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later</description>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <other_name>Brufen® syrup, Samil pharm. Co., Ltd.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Sodium chloride, Huons. Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. gestational age of 30 weeks or less or birth weight of 1250 g or less

          2. born in Samsung Medical Center

          3. confirmed to have hemodynamically significant patent ductus arteriosus (PDA) during
             day of life (DOL) 5 to 14

          4. Definition of hemodynamically significant PDA: at least one of clinical criteria plus
             at least one of echocardiographic criteria

               -  Clinical criteria

                    -  Respiratory signs, including tachypnea, chest retraction, increased
                       respiratory support, unable to wean respiratory support

                    -  Physical signs, including a murmur, hyperdynamic precordium or bounding
                       pulses

                    -  Blood pressure problems, including decreased mean or diastolic pressure or
                       increased pulse pressure

                    -  Signs of congestive heart failure, including cardiomegaly, hepatomegaly or
                       pulmonary congestion

               -  Echocardiographic criteria

                    -  Ductal size ≥ 1.5 mm

                    -  left atrium (LA)/Aorta ratio ≥1.5:1

                    -  Left-to-right shunting or bidirectional shunting with dominant left-to-right
                       blood flow (the presence of a color jet in the mean pulmonary artery)

        Exclusion Criteria:

          -  Mortality within the first 48 hours of life

          -  Right-to-left shunt or bidirectional shunting with dominant right-to-left shunt
             through PDA

          -  congenital anomaly

          -  bilateral intraventricular hemorrhage of grade 4

          -  contraindication of ibuprofen (bleeding diasthesis, platelet count 10,000/mm3 or less,
             serum creatinine 2.0 mg/dL or greater, necrotizing enterocolitis stage 2 or greater
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se In Sung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>February 11, 2018</last_update_submitted>
  <last_update_submitted_qc>February 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Se In Sung</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Patent ductus arteriosus</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

